GlobeNewswire Inc.··Not SpecifiedEupraxia Pharmaceuticals Advances EP-104GI Data Ahead of Key Medical Conference
Eupraxia Pharmaceuticals to present Phase 1b/2 clinical data for EP-104GI at Digestive Disease Week 2026, showcasing efficacy in eosinophilic esophagitis treatment.
EPRXEP-104GIeosinophilic esophagitis